The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives
Author:
Affiliation:
1. Department of Oncology, Faculty of medicine, Saint Joseph University, Beirut, Lebanon
2. Medical Oncology clinic, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium
3. Internal medicine, Vrije Universiteit, Brussels, Belgium
Abstract
Publisher
Future Medicine Ltd
Subject
Oncology,Immunology,Immunology and Allergy
Link
https://www.futuremedicine.com/doi/pdf/10.2217/imt-2017-0029
Reference54 articles.
1. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
2. Learning from the “tsunami” of immune checkpoint inhibitors in 2015
3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
4. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
5. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Organizational Impact of Immunotherapies in Advanced Cancers in France;JCO Global Oncology;2023-08
2. Toxicités immuno-induites chez les patients avec cancer sous immunothérapie par inhibiteurs des checkpoints. Ce que l’urgentiste doit savoir;Annales françaises de médecine d’urgence;2023-07
3. A framework for fibrolamellar carcinoma research and clinical trials;Nature Reviews Gastroenterology & Hepatology;2022-02-21
4. PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis;Turkish Journal of Medical Sciences;2022-01-01
5. PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare;Immunotherapy;2021-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3